Imatinib (commercial name: Gleevec) Attacks Prostate Cancer by Cutting off Blood Supply in Mouse Model
As reported by researchers from The University of Texas M. D. Anderson Cancer Center at the June 7 issue of the Journal of the National Cancer Institute, a medication used to treat other types of cancer strangles drug-resistant, metastatic prostate cancer by cutting off its blood supply.
The drug imatinib, commercially known as Gleevec, worked best when combined with the chemotherapy paclitaxel to slash the incidence of bone metastases and the size of tumors in mice injected with a multiple-drug resistant form of prostate cancer.
Read more at M.D. Anderson news.
Comment Preview